CL2017001438A1 - Antagonistas de miostatina o activina para el tratamiento de sarcopenia - Google Patents
Antagonistas de miostatina o activina para el tratamiento de sarcopeniaInfo
- Publication number
- CL2017001438A1 CL2017001438A1 CL2017001438A CL2017001438A CL2017001438A1 CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1 CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1
- Authority
- CL
- Chile
- Prior art keywords
- sarcopenia
- myostatin
- treatment
- activin antagonists
- activine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA, REGIMEN DE DOSIFICACIÔN Y SUS COMPOSICIONES FARMACÉUTICAS, PARA EL TRATAMIENTO DE SARCOPENIA, EN PARTICULAR, SARCOPENIA RELACIONADA CON IA EDAD. ESPECIALMENTE, SE HALLÓ QUE EL ANTAGONISTA DE MIOSTATINA O ACTIVINA BIMAGRUMAB ERA BENEFICIOSO EN EL TRATAMIENTO DE ADULTOS MAYORES CON SARCOPENIA, CON RESPECTO AL AUMERITO DE IA FUERZA Y FUNCION DEL MÜSCULO ESQUELETICO.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462088802P | 2014-12-08 | 2014-12-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017001438A1 true CL2017001438A1 (es) | 2018-02-16 |
Family
ID=55024187
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001438A CL2017001438A1 (es) | 2014-12-08 | 2017-06-07 | Antagonistas de miostatina o activina para el tratamiento de sarcopenia |
Country Status (17)
Country | Link |
---|---|
US (1) | US20170260275A1 (es) |
EP (1) | EP3229907A1 (es) |
JP (1) | JP2017538701A (es) |
KR (1) | KR20170094292A (es) |
CN (1) | CN106999589A (es) |
AU (2) | AU2015358939A1 (es) |
BR (1) | BR112017011411A2 (es) |
CA (1) | CA2969800A1 (es) |
CL (1) | CL2017001438A1 (es) |
IL (1) | IL252507A0 (es) |
MX (1) | MX2017007519A (es) |
PH (1) | PH12017500965A1 (es) |
RU (1) | RU2017123880A (es) |
SG (1) | SG11201704094QA (es) |
TN (1) | TN2017000217A1 (es) |
TW (1) | TW201627007A (es) |
WO (1) | WO2016092439A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5624276B2 (ja) | 2006-03-31 | 2014-11-12 | 中外製薬株式会社 | 抗体の血中動態を制御する方法 |
EP4368721A2 (en) | 2007-09-26 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in cdr |
MY195714A (en) | 2008-04-11 | 2023-02-07 | Chugai Pharmaceutical Co Ltd | Antigen-Binding Molecule Capable of Binding to Two or More Antigen Molecules Repeatedly |
KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
KR102273985B1 (ko) | 2012-08-24 | 2021-07-06 | 추가이 세이야쿠 가부시키가이샤 | FcγRIIb 특이적 Fc영역 개변체 |
WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
CN113621057A (zh) | 2013-04-02 | 2021-11-09 | 中外制药株式会社 | Fc区变体 |
MA41294A (fr) | 2014-12-19 | 2017-11-08 | Chugai Pharmaceutical Co Ltd | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation |
EP3253778A1 (en) | 2015-02-05 | 2017-12-13 | Chugai Seiyaku Kabushiki Kaisha | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
AU2017305073B2 (en) | 2016-08-05 | 2024-02-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for prevention or treatment of IL-8 related diseases |
US10485502B2 (en) * | 2016-12-20 | 2019-11-26 | General Electric Company | System and method for assessing muscle function of a patient |
JOP20190152A1 (ar) * | 2016-12-21 | 2019-06-20 | Novartis Ag | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
KR101917794B1 (ko) | 2018-05-10 | 2018-11-13 | 한국과학기술원 | 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물 |
KR101966117B1 (ko) | 2018-05-25 | 2019-04-05 | (주)녹십자웰빙 | 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물 |
KR102017282B1 (ko) | 2019-01-28 | 2019-09-02 | (주)녹십자웰빙 | 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
US20070190056A1 (en) * | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
TW201940502A (zh) * | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
TW201718635A (zh) * | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
NZ595235A (en) | 2009-04-27 | 2013-06-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
TW201210612A (en) * | 2010-06-03 | 2012-03-16 | Glaxo Group Ltd | Humanised antigen binding proteins |
WO2013006437A1 (en) * | 2011-07-01 | 2013-01-10 | Novartis Ag | Method for treating metabolic disorders |
CN104540961A (zh) * | 2012-06-11 | 2015-04-22 | 安姆根公司 | 双重受体拮抗性抗原结合蛋白及其用途 |
AU2014307589A1 (en) * | 2013-08-14 | 2016-02-11 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
TW201622746A (zh) * | 2014-04-24 | 2016-07-01 | 諾華公司 | 改善或加速髖部骨折術後身體復原之方法 |
-
2015
- 2015-12-04 MX MX2017007519A patent/MX2017007519A/es unknown
- 2015-12-04 WO PCT/IB2015/059369 patent/WO2016092439A1/en active Application Filing
- 2015-12-04 SG SG11201704094QA patent/SG11201704094QA/en unknown
- 2015-12-04 AU AU2015358939A patent/AU2015358939A1/en not_active Abandoned
- 2015-12-04 EP EP15816531.6A patent/EP3229907A1/en not_active Withdrawn
- 2015-12-04 RU RU2017123880A patent/RU2017123880A/ru not_active Application Discontinuation
- 2015-12-04 KR KR1020177018549A patent/KR20170094292A/ko unknown
- 2015-12-04 CN CN201580066991.6A patent/CN106999589A/zh not_active Withdrawn
- 2015-12-04 TW TW104140843A patent/TW201627007A/zh unknown
- 2015-12-04 JP JP2017530334A patent/JP2017538701A/ja not_active Withdrawn
- 2015-12-04 TN TN2017000217A patent/TN2017000217A1/en unknown
- 2015-12-04 BR BR112017011411A patent/BR112017011411A2/pt not_active Application Discontinuation
- 2015-12-04 CA CA2969800A patent/CA2969800A1/en not_active Abandoned
- 2015-12-04 US US15/529,594 patent/US20170260275A1/en not_active Abandoned
-
2017
- 2017-05-25 IL IL252507A patent/IL252507A0/en unknown
- 2017-05-25 PH PH12017500965A patent/PH12017500965A1/en unknown
- 2017-06-07 CL CL2017001438A patent/CL2017001438A1/es unknown
-
2019
- 2019-01-07 AU AU2019200082A patent/AU2019200082A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
TW201627007A (zh) | 2016-08-01 |
CN106999589A (zh) | 2017-08-01 |
CA2969800A1 (en) | 2016-06-16 |
BR112017011411A2 (pt) | 2018-02-14 |
RU2017123880A3 (es) | 2019-08-29 |
EP3229907A1 (en) | 2017-10-18 |
KR20170094292A (ko) | 2017-08-17 |
AU2019200082A1 (en) | 2019-01-31 |
MX2017007519A (es) | 2017-08-22 |
IL252507A0 (en) | 2017-07-31 |
WO2016092439A1 (en) | 2016-06-16 |
JP2017538701A (ja) | 2017-12-28 |
RU2017123880A (ru) | 2019-01-10 |
AU2015358939A1 (en) | 2017-06-15 |
TN2017000217A1 (en) | 2018-10-19 |
US20170260275A1 (en) | 2017-09-14 |
SG11201704094QA (en) | 2017-06-29 |
PH12017500965A1 (en) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001438A1 (es) | Antagonistas de miostatina o activina para el tratamiento de sarcopenia | |
CL2016001933A1 (es) | Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct | |
SV2017005426A (es) | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos | |
SV2017005471A (es) | Derivados de quinazolina utilizados para tratar el vih | |
CL2017000533A1 (es) | Pirrolopirimidinas para uso en la infección por el virus de la gripe | |
CL2013003019A1 (es) | Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih. | |
CL2016001963A1 (es) | Heteroarilos inhibidores de syk | |
EA201791310A1 (ru) | Химерные антигенные рецепторы к bcma | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
CL2017000309A1 (es) | Indoles para su uso en la infección por el virus de la gripe | |
MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
CL2014002915A1 (es) | Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico. | |
GT201700150A (es) | Derivados de glucagón con estabilidad mejorada | |
DK3229810T3 (da) | Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler | |
CL2017000391A1 (es) | Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea | |
BR112016023494A2 (pt) | método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados. | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
CU20170018A7 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo | |
DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
CL2017000152A1 (es) | Derivados de isoindolinona | |
CL2016002562A1 (es) | Régimen de dosificación de liberación inmediata de moduladores s1p. | |
BR112017001221A2 (pt) | derivados de indolizina que são aplicáveis a doenças neurodegenerativas | |
BR112017013580A2 (pt) | combinações de inibidor de btk e regime de dosagem. | |
TWD174815S (zh) | 瓶子 |